Bayers Halts Asundexian AFib Trial, OCEANIC-AF, for Inferior Efficacy - HCPLive

Retrieved on: 2023-11-20 21:03:57

Tags for this article:

Stroke

Atrial fibrillation

Direct factor Xa inhibitors

Embolism

Transient ischemic attack

Management of atrial fibrillation

Dabigatran

Bayer AG

Click the tags to see associated articles and topics

Bayers Halts Asundexian AFib Trial, OCEANIC-AF, for Inferior Efficacy - HCPLive. View article details on HISWAI: https://www.hcplive.com/view/bayers-halts-asundexian-afib-trial-oceanic-af-for-inferior-efficacy

Excerpt

... atrial fibrillation at risk for stroke. Announced by Bayer on November ... Interpreting the Clinical Benefit of Abelacimab for Atrial Fibrillation, with ...

Article found on: www.hcplive.com

View Original Article